The blood-brain barrier is a major hurdle in treating a whole range of diseases affecting the CNS. While it serves a vital role in protecting against...
Estimated as a $3 billion opportunity for Bioasis Technologies, the company's xB3 platform is set to revolutionize the treatment of neurological disease. The technology helps deliver...
Bioasis Technologies’ new xB3 platform overcomes a major hurdle in the fight against neurological disease: the blood-brain barrier (BBB). Potentially worth billions of dollars in licensing...
EPFL spin-off GliaPharm announced a $1.55 million (CHF 1.5 million) fund raising from the American company Gliaven LLC, bringing the total amount raised by the biotech...